A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
A prospective randomized study of acyclovir versus ganciclovir plus human immune globulin prophylaxis of cytomegalovirus infection after solid organ transplantation.
复制标题
一项关于阿昔洛韦与更昔洛韦加人免疫球蛋白预防实体器官移植后巨细胞病毒感染的前瞻性随机研究。
DOI：
10.1097/00007890-199403270-00019
复制
发表时间：
1994
期刊：
影响因子：
6.2
通讯作者：
Payne,WD
中科院分区：
文献类型：
--
作者：
Dunn,DL;Gillingham,KJ;Kramer,MA;Schmidt,WJ;Erice,A;BalfourJr,HH;Gores,PF;Gruessner,RW;Matas,AJ;Payne,WD
实体器官移植后经常发生巨细胞病毒病，并且与患者和同种异体移植物存活率下降有关。我们假设巨细胞病毒的传播或再激活在移植后立即或不久就开始了，并且以更昔洛韦（GCV*）为基础的短期治疗方案将减少长期抗病毒药物给药的需要，可能起到阻断巨细胞病毒感染和疾病的作用，甚至可能比以口服阿昔洛韦（ACV）为基础的更长期的预防形式更有效。共311例患者根据同种异体移植物类型、年龄、有无糖尿病进行分层，然后随机接受长期ACV预防（口服800 mg或400 mg ivqid，
Cytomegalovirus disease occurs frequently after solid organ transplantation and has been associated with decreased patient and allograft survival. We hypothesized that CMV transmission or reactivation begins immediately or soon after transplantation, and that a short-duration ganciclovir (GCV*)-based regimen would obviate the need for long-term antiviral agent administration, perhaps serving to interdict CMV infection and disease as well as, or perhaps even more effectively than, a more prolonged, oral acyclovir (ACV)-based form of prophylaxis. A total of 311 patients were stratified according to allograft type, age, and presence or absence or diabetes mellitus, and were then randomized to receive either long-duration ACV prophylaxis (800 mg orally or 400 mg ivqid for